Key result
Long-term steroid therapy linked to ~5-fold higher rate of endogenous hypertriglyceridemia in women.
Why the study?
Does long-term steroid therapy increase the prevalence of hyperlipidaemia (hypertriglyceridaemia and hypercholesterolaemia) in female asthmatic patients compared to normal female controls?
Cross-Sectional (n=150)
No
Does long-term steroid therapy increase the prevalence of hyperlipidaemia (hypertriglyceridaemia and hypercholesterolaemia) in female asthmatic patients compared to normal female controls?
Answers are grounded in this paper and cite their sources.
Long-term low-to-moderate dose steroid therapy in female asthmatic patients is associated with a significantly increased prevalence of endogenous hypertriglyceridaemia (21% vs 4%), independent of steroid dose, duration, obesity, or diabetes, without increasing hypercholesterolaemia.
Plasma lipids were measured in 100 female asthmatic patients receiving long-term steroid therapy. A significant increase in the incidence of endogenous hypertriglyceridaemia but not of hypercholesterolaemia was found. The hypertriglyceridaemia was not due to obesity or diabetes. Neither the dose of steroid, duration of therapy, nor the addition of corticotrophin gel or depot tetracosactrin influenced the prevalence of hypertriglyceridaemia.
No takes yet. Share an insight, caveat, or question.
El-Shaboury et al. (1973) conducted a cross-sectional in Asthma (n=150). Long-term steroid therapy (prednisone with or without corticotrophin gel or depot tetracosactrin) vs. Normal female subjects from a population survey not on steroid therapy was evaluated on Prevalence of endogenous hypertriglyceridaemia (Type IV hyperlipoproteinaemia) (p=<0.05). Long-term steroid therapy in female asthmatic patients was associated with a significantly higher prevalence of endogenous hypertriglyceridaemia compared to normal controls (21% vs 4%, p<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: